ASHP therapeutic position statement on the preferential use of metronidazole for the treatment of clostridium difficile-associated disease

American Journal of Health-System Pharmacy

Volumn 55, Issue 13, 1998, Pages 1407-1411

[No Author Info available]

Author keywords

American Society of Health System Pharmacists; Anti infective agents; Antibiotics; Clostridium infections; Costs; Dosage; Dosage schedules; Drug administration; Enterococcus species; Enterocolitis; Infection control; Metronidazole; Organizations; Pediatrics; Pharmacists; Protocols; Rational therapy; Resistance; Toxicity; Vancomycin

Indexed keywords

METRONIDAZOLE; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; CLOSTRIDIUM DIFFICILE; DIARRHEA; DRUG CHOICE; DRUG EFFICACY; HUMAN; ORAL DRUG ADMINISTRATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; RECURRENT DISEASE;

EID: 0032126842     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/55.13.1407     Document Type: Article

References (40)

1. Gerding DDN, Johnson S, Peterson LR et al. Clostridium difficile-associated diarrhea and colitis. Infect Control Hosp Epidemiol. 1995; 16:459-77.
2. Reinke CM, Messick CR. Update on Clostridium difficile-induced colitis, parts 1 and 2. Am J Hosp Pharm. 1994; 51:1771-81, 1892-901.
3. Fekety R. Guidelines for the diagnosis and management of Clostridium difficile-associated diarrhea and colitis. Am J Gastroenterol. 1997; 92:739-50.
4. Lai KK, Melvin ZS, Menard MJ et al. Clostridium difficile-associated diarrhea: epidemiology, risk factors, and infection control. Infect Control Hosp Epidemiol. 1997; 18:628-32.
5. Hirschhorn LR, Trnka Y, Onderdonk A et al. Epidemiology of community-acquired Clostridium difficile-associated diarrhea. J Infect Dis. 1994; 169:127-33.
6. Katz DA, Lynch ME, Littenberg B. Clinical prediction rates to optimize cytotoxin testing for Clostridium difficile in hospitalized patients with diarrhea. Am J Med. 1996; 100:487-95.
7. Olson MM, Shanholtzer CJ, Lee JT Jr et al. Ten years of prospective Clostridium difficile-associated disease surveillance and treatment at the Minneapolis VA medical center, 1982-1991. Infect Control Hosp Epidemiol. 1994; 15:371-81.
8. Nelson DE, Auerbach SB, Baltch AL et al. Epidemic Clostridium difficile-associated diarrhea: role of second-and third-generation cephalosporins. Infect Control Hosp Epidemiol. 1994; 15:88-94.
9. Manabe YC, Vinetz JM, Moore RD et al. Clostridium difficile colitis: an efficient clinical approach to diagnosis. Ann Intern Med. 1995; 123:835-40.
10. Riley TV, Cooper M, Bell B et al. Community-acquired Clostridium difficile-associated diarrhea. Clin Infect Dis. 1995; 20(suppl 2):S263-5.
11. Johnson S, Homann SR, Bettin KM et al. Treatment of asymptomatic Clostridium difficile carriers (fecal excretors) with vancomycin or metronidazole: a randomized, placebo-controlled trial. Ann Intern Med. 1992; 117:297-302.
12. Samore MH, DeGirolami PC, Tlucko A et al. Clostridium difficile colonization and diarrhea at a tertiary care hospital. Clin Infect Dis. 1994; 18:181-7.
13. Tedesco F, Markham R, Gurwith M et al. Oral vancomycin for antibiotic-associated pseudomembranous colitis. Lancet. 1978; 2:226-8.
14. Teasley DG, Olson MG, Gebhard RI et al. Prospective randomized trial of metronidazole versus vancomycin for Clostridium difficile-associated diarrhea and colitis. Lancet. 1983; 2:1043-6.
15. Anand A, Bahey B, Mir T et al. Epidemiology, clinical manifestations, and outcome of Clostridium difficile-associated diarrhea. Am J Gastroenterol. 1994; 89:519-23.
16. Wenisch C, Parschalk B, Hasenhundl M et al. Comparison of vancomycin, teicoplanin, metronidazole, and fusidic acid for the treatment of Clostridium difficile-associated diarrhea. Clin Infect Dis. 1996; 22:813-8.
17. Fekety R, McFarland LV, Surawicz CM et al. Recurrent Clostridium difficile diarrhea: characteristics of and risk factors for patients enrolled in a prospective, randomized, double-blinded trial. Clin Infect Dis. 1997; 24:324-33.
18. Centers for Disease Control and Prevention Hospital Infection Control Practices Advisory Committee. Recommendations for preventing the spread of vancomycin resistance. Infect Control Hosp Epidemiol. 1995; 16:105-13.
19. Clostridium difficile. In: Peter G, ed. American Academy of Pediatrics 1997 red book: report of the Committee on Infectious Diseases. 24th ed. Elk Grove Village, IL: American Academy of Pediatrics; 1997:177-8.
20. Gerding DN. Is there a relationship between vancomycin-resistant enterococcal infection and Clostridium difficile infection? Clin Infect Dis. 1997; 25(suppl 2):S206-10.
21. Fraise AP. The treatment and control of vancomycin-resistant enterococci. J Antimicrob Chemother. 1996; 38:753-6.
22. Carr JR, Fitzpatrick PE, Cumbo TJ et al. A reduction in oral vancomycin use and a concomitant reduction in vancomycin-resistant Enterococcus. Infect Control Hosp Epidemiol. 1996; 17(suppl):25. Abstract.
23. Rao GG, Ojo F, Kolokithas D. Vancomycin-resistant gram-positive cocci: risk factors for fecal carriage. J Hosp Infect. 1997; 35:63-9.
24. Rafferty ME, McCormick MI, Bopp LH et al. Vancomycin-resistant enterococci in stool specimens submitted for Clostridium difficile cytotoxin assay. Infect Control Hosp Epidemiol. 1997; 18:342-4.
25. Lam S, Singer C, Tucci V et al. The challenge of vancomycin-resistant enterococci: a clinical and epidemiologic study. Am J Infect Control. 1995; 23:170-80.
26. Van der Auwera P, Pensart N, Korten V et al. Influence of oral glycopeptides on the fecal flora of human volunteers: selection of highly glycopeptide-resistant enterococci. J Infect Dis. 1996; 173:1129-36.
27. Edlund C, Barkholt L, Olsson-Liljequist B et al. Effect of vancomycin on intestinal flora of patients who previously received antimicrobial therapy. Clin Infect Dis. 1997; 25:729-32.
28. Fekety R, Silva J, Kaufman C et al. Treatment of antibiotic-associated Clostridium difficile colitis with oral vancomycin: comparison of two dosage regimens. Am J Med. 1989; 86:15-9.
29. Bublin JG, Barton TL. Rectal use of vancomycin. Ann Pharmacother. 1994; 28:1357-8.
30. Oliva SL, Guglielmo BJ, Jacobs R et al. Failure of intravenous vancomycin and intravenous metronidazole to prevent or treat antibiotic-associated pseudomembranous colitis. J Infect Dis. 1989; 159:1154-5. Letter.
31. Kleinfeld D, Donta ST. Reply. (Failure of intravenous vancomycin and intravenous metronidazole to prevent or treat antibiotic-associated pseudomembranous colitis.) J Infect Dis. 1989; 159:1155. Letter.
32. Zwiener BJ, Belknap WM, Quan R. Severe pseudomembranous enterocolitis in a child: case report and literature review. Pediatr Infect Dis J. 1989; 8:876-82.
33. Evans ME, Kortas KJ. Vancomycin use in a university medical center: comparison with Hospital Infection Control Practices Advisory Committee guidelines. Infect Control Hosp Epidemiol. 1996; 17:356-9.
34. Metronidazole. In: Briggs GG, Freeman RK, Yaffe SJ, eds. Drugs in pregnancy and lactation: a guide to fetal and neonatal risk. 4th ed Baltimore: Williams & Wilkins; 1994:585-9.
35. Eddy JT, Stamatakis MK, Makela EH. Saccharomyces boulardii for the treatment of Clostridium difficile-associated colitis. Ann Pharmacother. 1997; 31:919-21.
36. Johnson SV, Hoey LL, Vance-Bryan K. Inappropriate vancomycin prescribing based on criteria from the Centers for Disease Control and Prevention. Pharmacotherapy. 1995; 15:579-85.
37. Watanakunakorn C. Prescribing pattern of vancomycin in a community teaching hospital with low prevalence of vancomycin-resistant enterococci. Infect Control Hosp Epidemiol. 1997; 18:767-9.
38. Carr JR, Fitzpatrick P, Izzo JL et al. Changing the infection control paradigm from off-line to real time: the experience at Millard Fillmore Health System. Infect Control Hosp Epidemiol. 1997; 18:255-9.
39. Beidas S, Khamesian M. Vancomycin use in a university medical center: comparison with Hospital Infection Control Practices Advisory Committee guidelines. Infect Control Hosp Epidemiol. 1996; 17:773-4. Letter.
40. Schlaes DM, Gerding DN, John JF Jr et al. Society for Health-care Epidemiology of America and Infectious Diseases Society of America Joint Committee on the Prevention of Antimicrobial Resistance: guidelines for the prevention of antimicrobial resistance in hospitals. Infect Control Hosp Epidemiol. 1997; 18:275-91.